drugset / Trial / NCT00064467

Lethargic Depression Study

NCT00064467

Phase 3 Completed 268 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a study of Major Depressive Disorder (MDD) in patients with decreased energy, pleasure and interests.

Timeline

Start
2003-06
Primary completion
2005-05
Completion
2005-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 300 mg
Subject Bupropion Small molecule 450 mg